Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lucitanib + nivolumab
- Development stage
- Phase 2
- Lead developer
- Clovis Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Lucitanib + nivolumab is an investigational combination therapy under clinical evaluation primarily for advanced and metastatic gynecological cancers. Lucitanib is an oral, small molecule, multi-tyrosine kinase inhibitor targeting FGFR1/2/3, VEGFR1-3, and PDGFRα/β to inhibit tumor angiogenesis and cell proliferation. Nivolumab is a monoclonal antibody immune checkpoint inhibitor targeting PD-1 (programmed death-1) to restore antitumor immunity. The combination aims to leverage antiangiogenic mechanisms with immune checkpoint blockade, seeking both direct antitumor and immunomodulatory effects, and is being studied for efficacy and safety in several advanced solid tumor subtypes, notably recurrent endometrial, cervical, ovarian, and clear-cell gynecologic cancers.
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on lucitanib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lucitanib + nivolumab.